A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Clinical trial NCT04613674 · COMPLETED

Trial details

NCT number: NCT04613674
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Triple Negative Breast Cancer

Start date: 2020-12-09
Primary completion: 2023-09-14
Enrollment: 441

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.